Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Lapatinib preparation method

A lapatinib and compound technology, which is applied in the field of drug synthesis, can solve the problems of stannyl furan compound pollution, reduced yield of coupling products, unstable boronic acid group, etc., and achieves reduction of production cost, reduction of reaction steps, and increase of solubility. big effect

Active Publication Date: 2015-12-02
SHANDONG LUOXIN PARMACEUTICAL GROUP STOCK CO LTD
View PDF7 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] Although this method solves the problem of highly toxic stannyl furan compounds polluting the environment, the yield of coupling products decreases due to the instability of boric acid groups and low organic solubility.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Lapatinib preparation method
  • Lapatinib preparation method
  • Lapatinib preparation method

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Preparation of 6-iodo-3,4-dihydroquinazolin-4-one (Ⅲ)

[0037] 2-Amino-5-iodobenzoic acid (II) (6.8g, 0.05mol), mixed with 20ml of formamide, heated at 180°C, stirred for 12h, cooled, poured into ice water, filtered, washed with water to obtain 6- Iodine-3,4-dihydroquinazolin-4-one (Ⅲ) needle crystal 12.6g, yield 92.6%, HPLC purity 99.83%.

Embodiment 2

[0039] Preparation of 6-iodo-3,4-dihydroquinazolin-4-one (Ⅲ)

[0040] 2-Amino-5-iodobenzoic acid (II) (6.8g, 0.05mol), mixed with 15ml of formamidine acetate, heated at 160°C, stirred for 12h, cooled, poured into ice water, filtered, washed with water to obtain 6 -Iodine-3,4-dihydroquinazolin-4-one (Ⅲ) needle crystal 12.4 g, yield 90.9%, HPLC purity 99.56%.

Embodiment 3

[0042] Preparation of 6-iodo-3,4-dihydroquinazolin-4-one (Ⅲ)

[0043] 2-Amino-5-iodobenzoic acid (II) (6.8g, 0.05mol), mixed with 20ml of formamide, heated at 100°C, stirred for 15h, cooled, poured into ice water, filtered, washed with water to obtain 6- Iodine-3,4-dihydroquinazolin-4-one (Ⅲ) needle crystal 11.7g, yield 86.7%, HPLC purity 99.72%.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a lapatinib preparation method. In the synthesis method, the initial raw materials of 2-amino-5-iodobenzoic acid and a cyclization reagent are used for preparing a midbody of 6-iodine-3,4-dihydroquinazoline-4-ketone (III), quinazoline sulfide (V) is generated through the midbody of 6-iodine-3,4-dihydroquinazoline-4-ketone (III) under the condition of sulpho-reagent and methine halide, and a target molecule is further synthesized. Due to reaction, the lapatinib yield of a final product is increased, generation of an unstable midbody of 4-chloroquinazoline product is avoided, meanwhile, use of corrosive phosphorus trichloride, phosphorus pentachloride, thionyl chloride, phosgene or phosphorus oxychloride and other chlorinating agents is avoided, and the lapatinib preparation method is suitable for industrial production.

Description

technical field [0001] The invention belongs to the technical field of drug synthesis, in particular to a preparation method of lapatinib. Background technique [0002] Lapatinib is a small molecule 4-anilinoquinazoline receptor tyrosine kinase inhibitor developed by GlaxoSmithKline, which belongs to the epidermal growth factor receptor (ErbB1) and human epidermal Dual inhibitor of factor receptor-2 (ErbB2). Lapatinib was reviewed and approved for marketing by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) on March 13 and December 14, 2007, respectively. Its trade name is Tykerb (Tekpo), used for Treatment of advanced or metastatic breast cancer. Lapatinib has the structural formula (I) and the chemical name N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-methylsulfonylethylamino)methyl Base]-2-furyl]quinazolin-4-amine. [0003] [0004] Currently lapatinib has several reports of different patent routes: [0005] 1) Preparati...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D405/04
CPCC07D405/04
Inventor 程楚王林森姚云成刘庆利
Owner SHANDONG LUOXIN PARMACEUTICAL GROUP STOCK CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com